← Back to Home

Adding a Control Dial to Gene Therapy: An RNA Switch Lets Drugs Regulate Protein Production

Once a gene enters cells, how can therapeutic protein production be increased or decreased when needed? A switch that uses cells’ own RNA-editing machinery showed metabolic improvements in obese mice, but precise control for human use remains some way off.

By SURL BioNews

Gene therapy aims to enable cells to produce therapeutic proteins over the long term, but continuous production also presents a challenge: when a condition changes or protein levels become excessive, can production be reduced? A team at the University of California San Diego has developed an RNA switch called an adaptamer that allows small-molecule drugs to help control protein production, taking a step toward adjustable gene therapy. The university announced the research, published in *Molecular Cell*, on November 13. The evidence remains preclinical.

The switch links drug recognition with RNA editing. According to an earlier preprint of the same study, its core is fewer than 120 base pairs long. When a drug binds, it stabilizes the RNA’s double-stranded structure, recruiting the cell’s existing ADAR editing enzymes to rewrite a signal that would otherwise stop protein production prematurely, allowing the downstream sequence to continue being translated. Control occurs at the RNA level and does not require rewriting the cell’s DNA.

This allows the genetic instructions delivered into cells to remain in place while protein production changes in response to the drug. According to the university’s explanation, drug concentration and exposure time affect switch activity, and protein production declines after the drug is withdrawn. However, this is not yet a calibrated control dial: further research is needed to determine how precisely drug doses can correspond to protein concentrations.

The team tested the therapeutic potential using fibroblast growth factor 21 (FGF21), a protein involved in metabolic regulation. This protein holds promise for improving obesity and metabolic abnormalities, but excessive or prolonged exposure may cause muscle loss and reduced bone density, highlighting the need to control production. The researchers therefore placed FGF21 under the control of the RNA switch, seeking to balance sustained supply with room for adjustment.

The earlier preprint provided details of the animal experiments: the researchers used an adeno-associated virus serotype 8 (AAV8) vector to deliver the switch-controlled FGF21 gene into mice with diet-induced obesity, then began administering tetracycline daily one week later. Mice receiving both the gene vector and the activating drug showed weight loss and improved glucose tolerance, while fat accumulation in liver sections almost completely disappeared. These results are consistent with the metabolic improvements described in the university’s news release and the version republished by Medical Xpress.

The results are encouraging, but the scale of the evidence must also be considered: the preprint’s FGF21 efficacy experiment included only four mice per group, and that version had not undergone peer review, so it cannot be treated as the final account of all details in the published paper. Metabolic improvements in animals are also insufficient to demonstrate that this approach can maintain long-term efficacy in humans or that it has avoided the risks associated with excessive FGF21.

The team next hopes to extend the controllable design to gene therapies for the brain and molecules that promote tissue repair. Moving toward clinical use will depend on establishing the range of control in different tissues, how quickly production falls after drug withdrawal, and the safety of repeated activation over the long term. This study offers a design that gives gene therapy room for adjustment, but further validation is needed before it can become a therapeutic tool that physicians can operate reliably.

References

  1. University of California San Diego
  2. bioRxiv preprint via PubMed Central
  3. Medical Xpress